Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab ; volume:11 ; number:1 ; year:2018 ; pages:17-20
Case reports in oncology ; 11, Heft 1 (2018), 17-20

Creator: Schwab, Katjana S.
Kristiansen, Glenn
Schild, Hans H.
Held, Stefanie E.A.
Heine, Annkristin
Brossart, Peter

DOI: 10.1159/000485562

URN: urn:nbn:de:101:1-201805242106

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:36 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Schwab, Katjana S.
Kristiansen, Glenn
Schild, Hans H.
Held, Stefanie E.A.
Heine, Annkristin
Brossart, Peter

Other Objects (12)

$Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma$

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

$Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma$

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

$Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial$

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

$Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma$

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

$Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma$

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

$Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial$

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

$Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma$

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

$Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma$

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

$Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial$

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Related objects

Reset password